![blue_cell](/sites/default/files/styles/paragraph_image_right_left_620x420/public/2020-05/1909_New_Glycostem_blue_NK-cell.png?itok=OA_e4RQr)
Pioneering, developing and manufacturing
Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK-cell production processes.During our phase I safety study we verified our lead product oNKord® (naked NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second generation product: Chimeric Antigen Receptor (CAR)-engineered NK cells. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.